ArticleGastrointestinal cancer research : GCR2008
The role of positron emission tomography in esophageal cancer.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial.Esophagus : official journal of the Japan Esophageal Society · 2022Trial
- The Predilection of Specific Diseases to Affect Different Sections of the Esophagus.Life (Basel, Switzerland) · 2025Review
- Impact of endoscopic ultrasonography with fine needle aspiration assessing clinical lymph node staging on radiotherapy treatment planning in esophageal cancer patients.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Management of early oesophageal cancer: An overview.World journal of gastrointestinal surgery · 2024Article
- Acceptance and disparities of PET/CT use in patients with esophageal or gastro-esophageal junction cancer: Evaluation of mature registry data.Frontiers in nuclear medicine · 2022Article
- Superiority of NBI endoscopy to PET/CT scan in detecting esophageal cancer among head and neck cancer patients: a retrospective cohort analysis.BMC cancer · 2020Article
- Ongoing Challenges with Clinical Assessment of Nodal Status in T1 Esophageal Adenocarcinoma.Journal of the American College of Surgeons · 2019Article
- Isolated Colonic Metastasis From Esophageal Adenocarcinoma.ACG case reports journal · 2019Article
- Is endoscopic ultrasound examination necessary in the management of esophageal cancer?World journal of gastroenterology · 2017Review
- Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.European journal of nuclear medicine and molecular imaging · 2013Article
- Clinical T2N0M0 carcinoma of thoracic esophagus.Journal of thoracic disease · 2010Article
- Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers.Gastrointestinal cancer research : GCR · 2009Article
- Positron emission tomography in esophageal cancer.Gastrointestinal cancer research : GCR · 2008Article
- 18F-FDG PET/CT imaging in oncology.Annals of Saudi medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common methods for staging esophageal cancer are endoscopic ultrasonography (EUS) and computed tomography (CT). EUS is well established in differentiating between early tumor stages and more advanced primary lesions. When combined with fine needle aspiration, EUS has become an important tool in assessing the regional lymph nodes, as well. EUS has its limitations, esophageal obstruction makes passage of the endoscope beyond the tumor nearly impossible and with a narrow field of evaluation, it is not useful for detecting metastatic disease. CT allows for assessment of local tumor invasion while simultaneously providing information regarding distant disease. Its usefulness locally, however, is limited. CT and EUS yield anatomic visualization. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) can provide functional information and is an effective diagnostic modality in esophageal cancer. Its role in the management of esophageal cancer includes staging as well as potential utility in the evaluation of neoadjuvant therapy response and in follow-up after definitive therapy. FDG-PET will likely be more readily used in combination with anatomical imaging like CT to provide additional diagnostic information to aid radiation oncologists in target delineation and planning. In addition, FDG-PET has also been shown to have prognostic value that can be applied to patient management and aid in development of emerging therapies.
Identifiers
19259317PMC2630808W2470468284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.